The cellular immunity in cancer patients: DNCB test and its prognostic implications

La inmunidad celular en los pacientes cancerosos: test del DNCB y sus implicancias pronósticas

Dighiero, Guillermo - Lassus, Mercedes - Lima, Fabio - Martínez de Lima, Gladys - Priario, Julio C

Resumen:

20 normal subjects and 72 neoplasic were testea for their ability to develop delayed cutaneous sensitivity to dinitrochlorobenzene (DNCB). There was astatistical!y significant difference between the reaction of normal subjects· (95 % positives) and neoplasic population ( 50 % ) . Patients who were able to react to DNCB had asignificantly better short-term (six and twelve months) prognosis than those who were anergic, and this correlation was also significant in those patients who exhibitedadvanced neoplasic disease. This study suggests that there might be a significant correlation between the reaction to DNCB and the course of malignant disease.


Se estudió la respuesta al 2-4 dinitroclorobenzeno (DNCB) en 20 sujetos normales y 72 neoplásicos. Se encontró que la diferencia de respuesta entre J.a población normal (95 % de positivos) y la neoplásica ( 50 % ) tiene alta significación estadística. La evolución a 6 meses y a un año mostró diferencias estadísticamente significativas entre los pacientesDNCB positivos y negativos. En los neoplasmas avanzados también se encontró diferencias estadísticamente significativas en la evolución de los positivos y los negativos.Se insiste en la posibilidad de que el DNCB pueda constituir un test de valor pronóstico en el estudio de los neoplásicos.


Detalles Bibliográficos
1974
tumores malignos
inmunidad
malign tumors
inmunity
Español
Sociedad de Cirugía del Uruguay
Revista Cirugía del Uruguay
https://revista.scu.org.uy/index.php/cir_urug/article/view/2592
Acceso abierto
Resumen:
Sumario:20 normal subjects and 72 neoplasic were testea for their ability to develop delayed cutaneous sensitivity to dinitrochlorobenzene (DNCB). There was astatistical!y significant difference between the reaction of normal subjects· (95 % positives) and neoplasic population ( 50 % ) . Patients who were able to react to DNCB had asignificantly better short-term (six and twelve months) prognosis than those who were anergic, and this correlation was also significant in those patients who exhibitedadvanced neoplasic disease. This study suggests that there might be a significant correlation between the reaction to DNCB and the course of malignant disease.